Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes

Affiliations

• ¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
• ² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
• ³ Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
• ⁴ Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
• ⁵ Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
• ⁶ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].